<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="73054798152 doi: 10.1134/S1068162020030139 : Article 5-(Perylen-3-ylethynyl)uracil Derivatives Inhibit Reproduction of" exact="Respiratory" post="Viruses NikolayevaY. V.1UlashchikE. A.2ChekerdaE. V.1GalochkinaA. V.1SlesarchukN. A.345ChistovA. A.35NikitinT. D.34KorshunV."/>
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="5-(perylen-3-ylethynyl)uridine and its ability to effectively inhibit the replication of" exact="respiratory" post="disease pathogens in cell culture, namely: influenza A virus"/>
 <result pre="and its ability to effectively inhibit the replication of respiratory" exact="disease" post="pathogens in cell culture, namely: influenza A virus (IVA);"/>
 <result pre="disease pathogens in cell culture, namely: influenza A virus (IVA);" exact="type 3" post="parainfluenza virus (PIV-3); and human respiratory syncytial virus (RSV)."/>
 <result pre="A virus (IVA); type 3 parainfluenza virus (PIV-3); and human" exact="respiratory" post="syncytial virus (RSV). Related known compounds were also analyzed:"/>
 <result pre="perylenylethynyluracil compounds nucleosides non-nucleoside derivatives antiviral activity influenza A virus" exact="respiratory" post="viruses INTRODUCTION Respiratory diseases are a significant problem affecting"/>
 <result pre="non-nucleoside derivatives antiviral activity influenza A virus respiratory viruses INTRODUCTION" exact="Respiratory" post="diseases are a significant problem affecting the health of"/>
 <result pre="less mortality than the influenza virus, the parainfluenza (PIV) and" exact="respiratory" post="syncytial (RSV) viruses are nevertheless dangerous. High-risk patients (preschool"/>
 <result pre="etiotropic drugs to treat illness caused by these pathogens, only" exact="symptomatic" post="treatments. Thus, there is an urgent need to develop"/>
 <result pre="is an urgent need to develop new, effective means of" exact="respiratory" post="virus control. Preparations featuring entirely new mechanisms of action,"/>
 <result pre="are highly active against a broad spectrum of enveloped viruses:" exact="herpes" post="simplex type 1 and type 2; Sindbis; hepatitis C;"/>
 <result pre="active against a broad spectrum of enveloped viruses: herpes simplex" exact="type 1" post="and type 2; Sindbis; hepatitis C; vesicular stomatitis [8â€&quot;11];"/>
 <result pre="broad spectrum of enveloped viruses: herpes simplex type 1 and" exact="type 2;" post="Sindbis; hepatitis C; vesicular stomatitis [8â€&quot;11]; tick-borne encephalitis [12];"/>
 <result pre="enveloped viruses: herpes simplex type 1 and type 2; Sindbis;" exact="hepatitis C;" post="vesicular stomatitis [8â€&quot;11]; tick-borne encephalitis [12]; African swine fever"/>
 <result pre="simplex type 1 and type 2; Sindbis; hepatitis C; vesicular" exact="stomatitis" post="[8â€&quot;11]; tick-borne encephalitis [12]; African swine fever [13]; and"/>
 <result pre="1 and type 2; Sindbis; hepatitis C; vesicular stomatitis [8â€&quot;11];" exact="tick-borne encephalitis" post="[12]; African swine fever [13]; and the influenza A"/>
 <result pre="and type 2; Sindbis; hepatitis C; vesicular stomatitis [8â€&quot;11]; tick-borne" exact="encephalitis" post="[12]; African swine fever [13]; and the influenza A"/>
 <result pre="2; Sindbis; hepatitis C; vesicular stomatitis [8â€&quot;11]; tick-borne encephalitis [12];" exact="African" post="swine fever [13]; and the influenza A virus serotypes"/>
 <result pre="properties, which, in turn, leads to inhibition of penetration of" exact="viral" post="genetic material into the cell (of the act of"/>
 <result pre="of a non-nucleoside derivative of cm1pUY11 (III) against enveloped viruses" exact="herpes" post="simplex type 1 [11] and tick-borne encephalitis [14]. Thus,"/>
 <result pre="non-nucleoside derivative of cm1pUY11 (III) against enveloped viruses herpes simplex" exact="type 1" post="[11] and tick-borne encephalitis [14]. Thus, the lipid nature"/>
 <result pre="(III) against enveloped viruses herpes simplex type 1 [11] and" exact="tick-borne encephalitis" post="[14]. Thus, the lipid nature of the proposed antiviral"/>
 <result pre="against enveloped viruses herpes simplex type 1 [11] and tick-borne" exact="encephalitis" post="[14]. Thus, the lipid nature of the proposed antiviral"/>
 <result pre="the antiviral activity of perylene compounds, in relation to other" exact="respiratory" post="viruses, been tested previously. The aim of this work"/>
 <result pre="in relation to the influenza A virus and two other" exact="respiratory" post="pathogens: type 3 parainfluenza virus and respiratory syncytial virus."/>
 <result pre="to the influenza A virus and two other respiratory pathogens:" exact="type 3" post="parainfluenza virus and respiratory syncytial virus. RESULTS AND DISCUSSION"/>
 <result pre="and two other respiratory pathogens: type 3 parainfluenza virus and" exact="respiratory" post="syncytial virus. RESULTS AND DISCUSSION Compound (IV) was prepared"/>
 <result pre="activity was tested in vitro against influenza A, human parainfluenza" exact="type 3," post="and respiratory syncytial virus. Data on their antiviral activity"/>
 <result pre="in vitro against influenza A, human parainfluenza type 3, and" exact="respiratory" post="syncytial virus. Data on their antiviral activity and cytotoxicity"/>
 <result pre="CC50/EC50 ratio Compounds Influenza A virus (IVA) Human parainfluenza virus" exact="type 3" post="(PIV-3) Human respiratory syncytial virus (RSV) CC50, Î¼M EC50,"/>
 <result pre="Influenza A virus (IVA) Human parainfluenza virus type 3 (PIV-3)" exact="Human respiratory syncytial virus" post="(RSV) CC50, Î¼M EC50, Î¼M SI CC50, Î¼M EC50,"/>
 <result pre="A virus (IVA) Human parainfluenza virus type 3 (PIV-3) Human" exact="respiratory" post="syncytial virus (RSV) CC50, Î¼M EC50, Î¼M SI CC50,"/>
 <result pre="characterized as having high antiviral activity against influenza, parainfluenza, and" exact="respiratory" post="syncytial viruses when tested in vitro using cell cultures."/>
 <result pre="Avance III 500Â MHz NMR spectrometer with signal attribution by" exact="residual" post="proton peaks in solvents: CDCl3 (7.26 ppm for 1H"/>
 <result pre="from this solution. A virus dilution (corresponding to multiplicity of" exact="infection" post="(m.o.i.) = 1) was prepared using culture media. Cell"/>
 <result pre="monolayers and then incubated for 72 h (37Â°C, 5% CO2)." exact="Viral" post="titers were determined by hemagglutination reaction. For this, culture"/>
 <result pre="physiological saline) was added. After 40 minutes, the presence or" exact="absence of" post="hemagglutination in the wells was visually assessed. Viral titers"/>
 <result pre="or absence of hemagglutination in the wells was visually assessed." exact="Viral" post="titers were calculated using the Reed and Mench method"/>
 <result pre="Reed and Mench method [20] and expressed as 50% tissue" exact="infection" post="doses (TID50) per 100 ÂµL volume. Drug antiviral activities"/>
 <result pre="ÂµL volume. Drug antiviral activities were estimated based on decreased" exact="viral" post="titers in relation to controls. Measurement of Antiviral Activity"/>
 <result pre="to controls. Measurement of Antiviral Activity against Parainfluenza Virus and" exact="Respiratory" post="Syncytial Virus HEp-2 cell culture, parainfluenza type 3 strain"/>
 <result pre="Parainfluenza Virus and Respiratory Syncytial Virus HEp-2 cell culture, parainfluenza" exact="type 3" post="strain v2932, and respiratory syncytial virus A2 were used"/>
 <result pre="Virus HEp-2 cell culture, parainfluenza type 3 strain v2932, and" exact="respiratory" post="syncytial virus A2 were used for analysis. Drugs were"/>
 <result pre="again (100 ÂµL per well at twice the original concentration)." exact="Viral" post="suspensions (100 ÂµL) were immediately added, and plates were"/>
 <result pre="and plates incubated for 6 days (at 37Â°C, 5%Â CO2)." exact="Viral" post="titers were determined using cellular immunoassay (cell-ELISA). For the"/>
 <result pre="and washed with PBS-T buffer. Next, a solution of mouse" exact="primary" post="antibodies (anti-parainfluenza virus HN protein) was applied and incubated"/>
 <result pre="room temperature with continuous stirring, followed by washing with buffer." exact="Secondary" post="antibodies were then applied and incubated again for 2"/>
 <result pre="of the solutions were measured at 450 nm. Presence of" exact="infection" post="was defined as sample optical densities exceeding those of"/>
 <result pre="defined as sample optical densities exceeding those of the controls." exact="Viral" post="titers were calculated by the Reed and Muench method"/>
 <result pre="724-67-15; e-mail: v-korshun@yandex.ru. ACKNOWLEDGMENTS The work was supported by the" exact="Russian" post="Science Foundation (RSF) grant no. 15-15-00053. A. A. Chistov"/>
 <result pre="2019â€&quot;February 2020), mankind was faced with a sudden outbreak of" exact="acute" post="respiratory illness (with significant mortality) caused by the SARS-CoV-2"/>
 <result pre="2020), mankind was faced with a sudden outbreak of acute" exact="respiratory" post="illness (with significant mortality) caused by the SARS-CoV-2 enveloped"/>
</results>
